Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Baxter
Dow
Express Scripts
McKinsey
Federal Trade Commission
Accenture
AstraZeneca

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,067,033

« Back to Dashboard

Which drugs does patent 8,067,033 protect, and when does it expire?

Patent 8,067,033 protects DUEXIS and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.
Summary for Patent: 8,067,033
Title:Stable compositions of famotidine and ibuprofen
Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
Inventor(s): Xu; Jerry (Hunt Valley, MD), Tidmarsh; George (Portola Valley, CA)
Assignee: Horizon Pharma USA, Inc. (Northbrook, IL)
Application Number:12/324,808
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;

Drugs Protected by US Patent 8,067,033

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,067,033

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,318,202 Stable compositions of famotidine and ibuprofen ➤ Sign Up
8,067,451 Methods and medicaments for administration of ibuprofen ➤ Sign Up
8,449,910 Stable compositions of famotidine and ibuprofen ➤ Sign Up
8,309,127 Stable compositions of famotidine and ibuprofen ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Army
Medtronic
Harvard Business School
AstraZeneca
Farmers Insurance
Queensland Health
Accenture
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.